米力农联合参麦注射液治疗肺心病心衰的临床疗效

Clinical efficacy of milrinone combined with Shenmai injection in the treatment of pulmonary heart disease and heart failure

目的探究米力农联合参麦注射液治疗慢性肺源性心脏病(肺心病)心力衰竭(心衰)的临床疗效。方法62例肺心病心衰患者,按照治疗方案的不同分为参照组及研究组,各31例。参照组患者采用常规治疗联合米力农治疗,研究组患者在参照组的基础上加用参麦注射液治疗。对比两组患者的临床疗效,治疗前后的心肌指数和心功能指标[心肌肌钙蛋白I(cTnI)、氨基末端B型利钠肽前体(NT-proBNP)、心率(HR)、左心室射血分数(LVEF)、每搏输出量(SV)]。结果研究组总有效率90.32%(28/31)高于参照组的67.74%(21/31),差异具有统计学意义(P<0.05)。治疗后,两组患者的cTnI、NT-proBNP、HR低于本组治疗前,LVEF、SV高于本组治疗前,且研究组患者的c TnI(5.63±1.06)μg/L、NT-proBNP(219.47±24.57)ng/L、HR(91.52±5.33)次/min低于参照组的(7.52±0.89)μg/L、(254.55±23.14)ng/L、(99.63±6.36)次/min,LVEF(41.52±3.45)%、SV(48.66±2.47)ml/次高于参照组(37.25±3.25)%、(41.22±2.58)ml/次,差异具有统计学意义(P<0.05)。结论米力农联合参麦注射液治疗肺心病心衰,对提高治疗效果具有显著意义,有助于改善患者的心功能,促进患者健康恢复,值得进一步推广。

Objective To investigate the clinical efficacy of milrinone combined with Shenmai injection in the treatment of pulmonary heart disease and heart failure.Methods A total of 62 patients with pulmonary heart disease and heart failure were divided into reference group and research group according to different treatment regimen,with 31 cases in each group.The reference group was treated with routine therapy and milrinone,and the research group was treated with Shenmai injection based on the reference group.The clinical efficacy,myocardial index and cardiac function index[cardiac troponin I(cTnI),N-terminal B-type natriuretic peptide precursor(NT-proBNP),heart rate(HR),left ventricular ejection fraction(LVEF),stroke volume(SV)]before and after treatment were compared between the two groups.Results The total effective rate of the research group was 90.32%(28/31),which was higher than 67.74%(21/31)of the reference group,and the difference was statistically significant(P<0.05).After treatment,the cTnI,NT-proBNP and HR of the two groups were lower than those before treatment,and the LVEF and SV were higher than those before treatment;the cTnI(5.63±1.06)μg/L,NT-proBNP(219.47±24.57)ng/L and HR(91.52±5.33)beats/min of the research group were lower than(7.52±0.89)μg/L,(254.55±23.14)ng/L and(99.63±6.36)beats/min of the reference group,and the LVEF(41.52±3.45)%and(48.66±2.47)ml/time were higher than(37.25±3.25)%and(41.22±2.58)ml/time of the reference group;all the difference was statistically significant(P<0.05).Conclusion Combination of milrinone and Shenmai injection has significant significance in improving the treatment effect of patients with pulmonary heart disease and heart failure,and it can improve the cardiac function and promote the recovery of patients,which is worthy of further promotion.